New scan could spot hidden tumors
NCT ID NCT04510311
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This early study tested a new radioactive tracer called [18F]3F-PHPG to see if it can help locate neuroendocrine tumors during PET scans. 32 adults with these tumors received the tracer and had two scans. The goal was to check image quality and how the tracer spreads in the body, which could lead to a better way to find and stage these tumors.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for NEUROENDOCRINE TUMORS are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
University of Michigan Rogel Cancer Center
Ann Arbor, Michigan, 48109, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- One dose may not fit all: blood tests could tailor cancer drug dosing
- Can a new 'Nanobody' tracer outsmart standard scans for neuroendocrine cancers?
- Can a Three-Drug cocktail shrink Hard-to-Treat neuroendocrine tumors?
- Experimental drug targets Hard-to-Treat neuroendocrine cancers
- New camera could make cancer treatment safer by better tracking radiation
- Radioactive drug targets hard-to-treat neuroendocrine tumors in early trial